Cortexyme, Inc. (NASDAQ:CRTX – Get Free Report)’s share price passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $1.16 and traded as high as $1.87. Cortexyme shares last traded at $1.73, with a volume of 218,043 shares traded.
Cortexyme Stock Performance
The company has a market capitalization of $52.16 million, a PE ratio of -0.58 and a beta of 1.40. The company’s 50-day moving average is $1.87 and its 200 day moving average is $1.17.
Cortexyme Company Profile
Cortexyme, Inc, a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection.
Further Reading
- Five stocks we like better than Cortexyme
- Which Wall Street Analysts are the Most Accurate?
- The Fed Is More Likely to Hike Than Cut Rates in 2025
- 3 Warren Buffett Stocks to Buy Now
- Investors Navigate Uncertainty by Seeking Refuge in Gold and Oil
- How to Invest in Blue Chip Stocks
- Archer Aviation Shares Slide, Now Bargain Priced for 2025
Receive News & Ratings for Cortexyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cortexyme and related companies with MarketBeat.com's FREE daily email newsletter.
